Free Trial

JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
Average Volume
267 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
JCRRF stock logo

About JCR Pharmaceuticals Stock (OTCMKTS:JCRRF)

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

JCRRF Stock Price History

JCRRF Stock News Headlines

JCR Pharmaceuticals Co Ltd 4552
JCR Pharmaceuticals earnings preview: what Wall Street is expecting
JCR Pharmaceuticals earnings preview: what to expect
JCR Pharmaceuticals Co Ltd (4552)
See More Headlines
Receive JCRRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Drug Manufacturers - General
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Not Optionable
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Shin Ashida (Age 81)
    Chairman, CEO & President
  • Yoshihiro Ota
    Director of Accounting Department & Corporate Strategy Department (Finance)
  • Yutaka Honda
    Senior Corporate Officer, Executive Director of Administration Div. & Director of Human Resources
  • Hiroyuki Fukuya
    Director of Legal Affairs Department - Administration Division
  • Toru Ashida (Age 56)
    Senior VP of Sales & Administration, Executive Director of Sales Division and Director
  • Ryutaro Makino
    Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.
  • Katsuya Nishino (Age 68)
    Executive Vice President
  • Hiroshi Yoshimoto (Age 73)
    Senior Advisor
  • Takayo Egawa
    Corporate Officer & Director of International Affairs Office
  • Mr. Hiroyuki Sonoda Ph.D. (Age 46)
    VP of Research & Corporate Strategy, Executive Director of Research Division and Director

JCRRF Stock Analysis - Frequently Asked Questions

Should I buy or sell JCR Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for JCR Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" JCRRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JCRRF, but not buy additional shares or sell existing shares.
View JCRRF analyst ratings
or view top-rated stocks.

How have JCRRF shares performed in 2024?

JCR Pharmaceuticals' stock was trading at $9.04 on January 1st, 2024. Since then, JCRRF shares have decreased by 42.3% and is now trading at $5.22.
View the best growth stocks for 2024 here

Are investors shorting JCR Pharmaceuticals?

JCR Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 512,400 shares, a decrease of 7.0% from the April 15th total of 551,200 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
View JCR Pharmaceuticals' Short Interest

How do I buy shares of JCR Pharmaceuticals?

Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:JCRRF) was last updated on 5/25/2024 by Staff

From Our Partners